Monitor PDUFA date (Jan 30, 2027) for approval decision. Approval would expand Joenja's eligible pediatric population, potentially driving incremental revenue. Near-term focus on commercial execution for the recently approved ≥27 kg cohort.
Price Chart
Executive Summary
Pharming announced FDA acceptance and Priority Review of its sNDA for lower doses of Joenja (leniolisib) in children aged 4+ weighing 13-27 kg with APDS. The PDUFA target action date is January 30, 2027. This expands the potential pediatric patient population beyond the recently approved ≥27 kg cohort.
Key Facts
- FDA accepted sNDA for lower doses of Joenja in children aged 4+ weighing 13-27 kg with APDS
- Priority Review granted with PDUFA target action date of January 30, 2027
- sNDA supported by positive Phase III data showing reduced lymphadenopathy and increased naive B cells over 12 weeks
- Joenja already approved in U.S. for adults/pediatric 12+ (March 2023) and children 4-11 weighing ≥27 kg (September 2026)
- APDS affects approximately 1-2 people per million worldwide
Financial Impact
Expansion of addressable pediatric APDS population by including children 13-27 kg; no revenue estimates provided
Risk Factors
- FDA may issue CRL on CMC or other grounds, delaying or denying approval
- Lower-weight pediatric dosing may have different safety/efficacy profile than approved doses
- Small patient population limits revenue upside even with expanded label
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3369191 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $11.55 | awaiting T+1 | awaiting T+1 | $11.87 (+2.77%) |
Oct 27, 2026 1d ago | Press Release | $11.55 | awaiting T+1 | awaiting T+1 | $11.87 (+2.77%) |
Oct 22, 2026 5d ago | 6-K | $10.67 $11.20 | ▲ +4.97% | ▲ +5.49% | $11.87 (+11.25%) |
Oct 14, 2026 13d ago | 6-K | $9.64 $9.63 | ▼ −0.10% | ▼ −0.39% | $11.87 (+23.13%) |
Sep 29, 2026 28d ago | 6-K | $10.01 $9.99 | ▲ +0.20% | ▼ −0.01% | $11.87 (−18.58%) |
Sep 29, 2026 29d ago | Press Release | $10.01 $9.99 | ▲ +0.20% | ▼ −0.01% | $11.87 (−18.58%) |
Sep 25, 2026 4w ago | 6-K | $10.46 $10.52 | ▲ +0.57% | ▲ +1.32% | $11.87 (+13.48%) |
Sep 25, 2026 4w ago | Press Release | $10.46 $10.52 | ▲ +0.57% | ▲ +1.32% | $11.87 (+13.48%) |
Sep 22, 2026 5w ago | 6-K | $11.26 $10.77 | ▼ −4.35% | ▼ −3.63% | $11.87 (+5.42%) |
Sep 11, 2026 6w ago | 6-K | $11.21 $10.82 | ▼ −3.48% | ▼ −3.03% | $11.87 (+5.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers